Butchaiah Garlapati, MD
Pain Medicine · N Little Rock, ARNPI 1326035163
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Saluda Medical Americas, Inc. at 26.3% of the total. Reporting peaked in 2024 at $2,858 and has fallen 93.6% since, to $183 in 2025.
Across 165 payments — averaging $55.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$2K
- Spinal Simplicity, LLC$2K
- Vertiflex, Inc.$1K
- Relievant Medsystems, Inc.$889
- Abbott$456
- AbbVie$323
- plus $2K from 28 others
What the payments were for
- Travel & lodging$4,20446%
- Food & beverage$3,40437%
- Education$1,54517%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Saluda Medical Americas, Inc. | 7 | $2,408 |
| Spinal Simplicity, LLC | 5 | $1,941 |
| Vertiflex, Inc. | 9 | $1,364 |
| Relievant Medsystems, Inc. | 6 | $889 |
| Abbott | 18 | $456 |
| AbbVie(2 entities) | 22 | $323 |
| Collegium Pharmaceutical, Inc. | 27 | $291 |
| Scilex Pharmaceuticals Inc. | 4 | $289 |
| Amgen(2 entities) | 14 | $207 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $139 |
| Boston Scientific | 5 | $116 |
| Nalu Medical, Inc. | 3 | $84 |
| Si-bone, Inc. | 2 | $80 |
| Redhill Biopharma Inc. | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $58 |
| Lundbeck LLC | 3 | $56 |
| Novartis | 3 | $50 |
| GRT US Holding, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $32 |
| AstraZeneca(2 entities) | 2 | $31 |
| Globus Medical | 2 | $29 |
| Lilly USA, LLC | 2 | $24 |
| Biodelivery Sciences International, Inc. | 1 | $21 |
| Biotronik NRO, Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Kaleo, Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
| MDD US Operations, LLC | 1 | $11 |
| Stimwave Technologies Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$3,005
- Evoke$2,255
- HA MINUTEMAN G3-R$1,881
- Superion ISS$1,245
- ZTLido$240
How this compares
$9,152 in reported general payments places this provider in the 80th percentile of 53 pain medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,029 | $62,371 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,793 | $55,183 |
| BotoxOnabotulinumtoxina | 37 | $50,379 |
| Oxycodone Hcl | 1,680 | $24,519 |
| OxycontinOxycodone Hcl | 45 | $15,539 |
| Xtampza ErOxycodone Myristate | 38 | $11,853 |
| Morphine Sulfate ErMorphine Sulfate | 636 | $10,713 |
| Gabapentin | 721 | $9,064 |
| Morphine Sulfate | 358 | $8,421 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 108 | $6,736 |
| Naloxone Hcl | 83 | $5,868 |
| Cyclobenzaprine Hcl | 488 | $4,507 |
| Tizanidine Hcl | 433 | $3,816 |
| Diclofenac Sodium | 117 | $3,548 |
| Pregabalin | 173 | $3,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $323 | $50,37937 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl | $19 | $20,446541 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $291 | $11,85338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 53 pain medicine providers in Arkansas.
Other pain medicine in N Little Rock
- Annette MeadorN Little Rock$16
- Stephen PaulusLittle Rock$75K
- Mark MiedemaFayetteville$35K
- George ArcosConway$30K
- George DeimelFayetteville$26K
- Julio OlayaLittle Rock$22K
- Maria Lyuksyutova-PriceMountain Home$19K
- Daniel JudkinsConway$17K
- Sheffield KentConway$16K
- Christopher MocekLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.